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SUMO conjugation to proteins is involved in the
regulation of diverse cellular functions. We have
identified a protein, RWD-containing sumoyla-
tion enhancer (RSUME), that enhances overall
SUMO-1, -2, and -3 conjugation by interacting
with the SUMO conjugase Ubc9. RSUME in-
creases noncovalent binding of SUMO-1 to
Ubc9 and enhances Ubc9 thioester formation
and SUMO polymerization. RSUME enhances
the sumoylation of IkB in vitro and in cultured
cells, leading to an inhibition of NF-kB tran-
scriptional activity. RSUME is induced by hyp-
oxia and enhances the sumoylation of HIF-1a,
promoting its stabilization and transcriptional
activity during hypoxia. Disruption of the RWD
domain structure of RSUME demonstrates that
this domain is critical for RSUME action. To-
gether, these findings point to a central role of
RSUME in the regulation of sumoylation and,
hence, several critical regulatory pathways in
mammalian cells.
INTRODUCTION
Small ubiquitin-related modifiers (SUMOs) are small
(12 kDa) proteins with low sequence identity to ubiquitin
but very similar 3D structure. To date, four SUMO family
members have been described in vertebrates: SUMO-1-
4 (Melchior, 2000; Hay, 2001; Guo et al., 2004).
SUMO is conjugated to proteins in three enzymatic
steps analogous to the ubiquitin conjugation cascade.
First, SUMO is activated by forming a thioester bond
with the catalytic cysteine of an E1 activating complex(SAE I + SAE II in mammalian cells) in an ATP-dependent
process and is then transferred to the catalytic cysteine of
the SUMO E2 enzyme, known as Ubc9, that conjugates
SUMO to the 3-amino group of a lysine side chain on the
substrate (Melchior, 2000). Unlike ubiquitination, which re-
quires an E3 ligase to complete the final transfer from the
E2 to the substrate protein, sumoylation can occur without
E3 ligases in vitro, although somewhat inefficiently (Hay,
2005). However, several SUMO E3 ligases, such as Ran-
BP2 (Pichler et al., 2002), whose mechanism of action
has been described in detail (Pichler et al., 2002; Reverter
and Lima, 2005), and the protein inhibitor of activated sig-
nal transducer and activator of transcription (PIAS) family
(Johnson and Gupta, 2001; Hochstrasser, 2001) interact
with Ubc9 and are essential for the correct sumoylation
of proteins in vivo (Hay, 2005). SUMO is removed from
substrates by specific cysteine proteases (SUMO isopep-
tidases) called SENPs (Melchior et al., 2003).
Sumoylation regulates diverse cellular functions, includ-
ing transcription (Girdwood et al., 2004), nuclear translo-
cation (Gill, 2004), stress response (Saitoh and Hinchey,
2000), and chromatin structure (Kim et al., 2006). In
some proteins, SUMO conjugation can take place on the
same lysine residues that are targets for ubiquitin conjuga-
tion. Sumoylated lysines cannot be ubiquitinated, thus re-
sulting in a stabilization of the target protein. This can lead
to functional consequences, as in the case of IkB, whose
stabilization by SUMO results in the inhibition of NF-kB
transcriptional activity (Desterro et al., 1998).
The RWD domain has been recently named after three
major RWD-containing proteins—RING finger-containing
proteins, WD-repeat-containing proteins, and yeast DEAD
(DEXD)-like helicases—and proposed as a protein-pro-
tein interaction domain (Doerks et al., 2002), although
functional studies have not been performed yet. The
structure of the mouse GCN2 RWD domain was deter-
mined, revealing significant structural homology to theCell 131, 309–323, October 19, 2007 ª2007 Elsevier Inc. 309
Figure 1. Cloning and Sequence Analysis of RSUME
(A) cDNA and deduced amino acid sequence of rat RSUME. The sequence of the fragment recovered from the differential display is highlighted in
blue.
(B) mRNA differential display of pituitary GH3 cells stably transfected with a gp130 expression vector (C8) or the empty vector (WT). The arrow
indicates the band identified as RSUME.
(C) Differential expression of RSUME was confirmed by northern blot analysis of mRNA obtained from GH3 control cells and C8 cells hybridized with
the cloned band. Loading was assessed by b-actin.310 Cell 131, 309–323, October 19, 2007 ª2007 Elsevier Inc.
mammalian SUMO conjugating enzyme Ubc9, despite
a sequence similarity of only 13%. This core structure
appears to be common among various RWD-contain-
ing proteins, although variations on the surface resi-
dues responsible for a putative protein-protein interac-
tion specificity suggest specific roles for different
RWD-containing proteins (Nameki et al., 2004).
In this work, we report the isolation and characterization
of RSUME, a previously unknown gene coding for a small
RWD domain-containing protein. RSUME was cloned
from a pituitary cell line with an increased tumorigenic
and angiogenic potential (Perez Castro et al., 2003). It is
upregulated by cellular stress stimuli such as hypoxia
and heat shock. RSUME enhances protein sumoylation
through a direct interaction with Ubc9. These actions
have functional implications on the NF-kB/IkB pathway
and on the regulation of hypoxia inducible factor-1a
(HIF-1a), both involved in angiogenesis and tumorigenic
processes.
RESULTS
Identification of RSUME, an RWD-Containing
Protein
We have previously generated stable clones from the rat
pituitary lactosomatotrophic tumor cell line GH3 that
show increased tumorigenic and angiogenic potential
when injected into nude mice (Perez Castro et al., 2003).
By differential display assay we compared one clone
against a control GH3 clone stable for the empty vector.
The differential bands were isolated, cloned, and se-
quenced. A previously uncharacterized mRNA (AF271158)
coding for a putative protein of 267 amino acids (Figure 1A)
appeared in two independent experiments (Figure 1B). A
northern blot probed with the cloned sequence confirmed
the differential expression (Figure 1C). According to the
NCBI Conserved Domain Database, this protein has a sin-
gle RWD domain spanning half its length (Figure 1D) and is
thus referred to as RWD-domain-containing protein 3
(Rwdd3). For this reason and considering its function de-
scribed in this work, we called this protein RSUME (for
RWD-domain-containing sumoylation enhancer). RSUME
is highly conserved in higher vertebrates (Figure 1D). Con-
served hypothetical proteins with lower identity have been
found in simpler organisms (Drosophila, NP_656300; ze-
brafish, XP702352.1; sea urchin, XP001200069.1).
RSUME does not seem to belong to any previously known
protein family.
The human RSUME protein is composed of 195 amino
acids, with a putative molecular mass of 21 kDa. The
sequence analysis revealed no consensus localization
signal, and therefore by default the predicted localizationof the protein was the cell’s cytoplasm. This issue was
addressed by subcloning RSUME as a GFP-fusion chi-
mera and transfecting the construct into different cell
lines. Despite lacking a nuclear localization signal,
when observed under a confocal fluorescence micro-
scope, N-terminal GFP-RSUME was found to be distrib-
uted in the nucleus and cytoplasm (Figure 1E). Similar
results were obtained with the C-terminal GFP fusion
protein.
RSUME Tissue Distribution and Expression
RSUME tissue distribution was studied in a commercial
poly-A RNA dot blot membrane (Human Multiple Tissue
Expression (MTE) Array, Clontech). RSUME is expressed
in various tissues, with higher expression levels in cerebel-
lum, pituitary, heart, kidney, liver, stomach, pancreas,
prostate, and spleen (Figure 2A). Moreover, RSUME ex-
pression is induced in GH3 cells under stress conditions
such as hypoxia, CoCl2, and heat shock (Figure 2B).
RSUME expression in pituitary tumors is increased by
hypoxia (Figure 2C). Furthermore, it is expressed in glioma
tumors (Figure 2C). In two gliomas in which two clearly
different regions could be identified, we found RSUME
expression in the necrotic inner zone but not in the periph-
eral zone of the tumor (Figure 2C).
RSUME Enhances Protein Sumoylation In Vitro
and In Vivo
The RWD domain presents a significant structural similar-
ity with the SUMO conjugase Ubc9 (Nameki et al., 2004),
and heat shock and hypoxia, which induce RSUME, also
induce SUMO-1 expression or increase protein sumoyla-
tion by SUMO-2/-3 (Saitoh and Hinchey, 2000; Shao et al.,
2004). In view of the aforementioned, we tested whether
RSUME is involved in protein sumoylation. Western blot
(WB) against SUMO-1 showed increased protein sumoy-
lation when RSUME was overexpressed in COS-7 cells
(Figure 3A). RSUME did not change E1 levels
(Figure 3A). Cotransfection with the SUMO hydrolase
Senp-1 confirmed that the observed pattern corresponds
to SUMO-conjugated proteins (Figure 3A). In a parallel
control experiment, RSUME did not affect protein ubiqui-
tination (Figure 3B).
We next characterized the action of RSUME on IkB.
Recombinant RSUME was added to a cell-free in vitro
sumoylation reaction. Addition of recombinant RSUME
increased SUMO-1 conjugation, indicating a direct effect
of RSUME on the core sumoylation machinery (Fig-
ure 3C). Despite its structural similarity with Ubc9, the
RWD domain lacks a Cys residue structurally equivalent
to Ubc9’s Cys 93, and a sumoylation reaction performed(D) Blast search to identify RSUME’s protein homologs. Ortholog proteins with significant identity were found in humans, mouse, dog, chicken, and
chimpanzee. A sequence alignment for human, mouse, and rat RSUME is shown. The RWD domain is underlined.
(E) Cellular distribution of N-terminal EGFP-RSUME visualized by confocal fluorescence microscopy (green). Nuclei were stained with propidium io-
dide (red). Merged images of both channels are included, with yellow representing overlapping signal. One representative image of 30 observations
from two independent experiments with similar results is shown.Cell 131, 309–323, October 19, 2007 ª2007 Elsevier Inc. 311
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without Ubc9 confirmed that RSUME lacks SUMO conju-
gase activity (Figure 3C).
Structural studies of the RWD domain revealed a highly
conserved YPXXXP motif (Nameki et al., 2004). When we
mutated this motif in RSUME in Tyr 61 and Pro 62 (two
amino acids proposed to be critical to maintain the struc-
tural backbone of the domain structure) (Nameki et al.,
2004) to alanine, sumoylation was no longer increased
(Figure 3C). This suggests that the correct folding of
RWD’s domain is essential for RSUME activity.
To determine the functional relation of RSUME and
Ubc9, we transfected COS-7 cells with RSUME together
with Ubc9(C93S). This mutant was described previously
to lack SUMO conjugase activity (Gong et al., 1997) and
also to act as a dominant-negative by blocking endoge-
nous Ubc9 (Giorgino et al., 2000), and is thus an ideal
tool to address this question. As shown in Figure 3D,
when Ubc9(C93S) was overexpressed, RSUME expres-
sion did not increase sumoylation, and enhanced the
inhibitory effect of Ubc9(C93S). When Ubc9 and Ubc9
(C93S) were simultaneously overexpressed, the enhanc-
ing effect on Ubc9(C93S) disappeared only when similar
amounts of both plasmids were transfected (Figure 3D, in-
set). These effects of RSUME were also manifest with
SUMO-2 and SUMO-3, which use the same conjugase
(Figure 3D). Ubc9(C93S) produced a slight decrease in
RSUME levels, which did not affect the observed effects
of RSUME (Figure 3D). These results indicate that (1)
RSUME increases sumoylation by means of the catalytic
activity of Ubc9 and that (2) RSUME also increases the
negative effect of Ubc9(C93S) on sumoylation. These re-
sults support a direct role for RSUME facilitating the
interaction of Ubc9 with the rest of the SUMO-conjugation
complex.
To establish at which step RSUME acts, we performed
a two-step in vitro sumoylation experiment, where
RSUME was added either during the formation of the
Ubc9-SUMO-1 thioester or during the transference of
SUMO-1 from the thioester to a substrate (IkB). RSUME
acted at both steps, although the strongest effect was
seen when it was added during the formation of the thio-
ester, in the absence of substrate (Figure 3E). Accordingly,
RSUME enhanced Ubc9 thioester formation (Figure 3F).
RSUME also enhanced Ubc9-mediated polymerization
of SUMO-2 and SUMO-3 free chains (Figure 3G).
We next compared the activity of RSUME to that of the
E3 ligase PIAS1, showing that when both were added
together there was a stronger effect on overall sumoyla-
tion (Figure 3H).RSUME Physically Interacts with Ubc9
and SUMO-1
The previous results suggested a direct interaction be-
tween RSUME and Ubc9. To address this hypothesis,
we performed an in vitro pull-down experiment using re-
combinant GST-Ubc9 and RSUME, showing that RSUME
interacts with Ubc9 (Figure 4A). Further immunoprecipita-
tion experiments showed that RSUME could also interact
with SUMO-1 (Figure 4B).
In competition experiments,RSUMEenhancedSUMO-1
binding to Ubc9 (lower concentrations of SUMO-1 only in-
teracted with Ubc9 when RSUMEwas present) (Figure 4C)
in the presence or absence of E1 (see Figure S1 in the Sup-
plemental Data available with this article online). When
RSUME and Ubc9 assembly had been previously pre-
formed, SUMO-1 did not displace RSUME binding to
Ubc9 (left panel of Figure 4D). When all proteins competed
simultaneously, higher concentrations of SUMO-1 pre-
vented RSUME-binding to Ubc9 (lane 9 Figure 4A, lane 4
Figure 4C, and lane 3 right panel of Figure 4D; lane 5
Figure 4C and lane 4 right panel of Figure 4D).
To further understand RSUME’s action, we studied its
effect on the interaction of Ubc9 with E1 and found that
RSUME increased the binding of Ubc9 and E1 (Figure 4E).
The interaction of RSUME to Ubc9 was confirmed in
COS-7 cell extracts using GST-Ubc9 (Figure 4F). To ex-
plore whether this interaction was supported by the intra-
cellular localization of RSUME and Ubc9, COS-7 and
HeLa cells were cotransfected with EGFP-RSUME and
RFP-Ubc9 constructs. A confocal microscopy examina-
tion showed a predominantly nuclear localization for
Ubc9, as reported previously (Lee et al., 1998), and
nuclear and cytoplasmic localization for RSUME. The
merged image revealed defined nuclear spots where the
colocalization of both proteins can be observed (Fig-
ure 4G). Together, these results strongly point to a direct
interaction between RSUME and Ubc9.
RSUME Increases IkB Levels by Promoting Its
Sumoylation and Inhibits NF-kB Transcriptional
Activity and Target Expression
We next examined the functional consequences of the
observed action of RSUME on IkB sumoylation in mam-
malian cells. Transfection of COS-7 cells with RSUME re-
sulted in increased IkB sumoylation and protein stability
(Figure 5A). The increased levels of IkB observed in
Figure 5A are most likely due to a dynamic equilibrium of
IkB with the increased sumoylated IkB pool that is refrac-
tory to degradation and leads to an increased stability ofFigure 2. Tissue Distribution and Expression of RSUME
(A) Tissue distribution of RSUME studied by hybridizing a commercial polyA mRNA dot blot membrane with the RSUME cDNA probe followed by
a semiquantitative densitometric analysis. Tissues with the most significant expression levels are shaded in gray.
(B) RT-PCR to detect endogenous RSUME expression in pituitary GH3 cells under different stress conditions. Hypoxia: 1%O2, 5%CO2, 94%N2 for 1
hr. Heat shock: 15 min at 42C, then 1 hr at 37. CoCl2: 2% serumwith 150 mMCoCl2 for 3 hr. Densitometric values were normalized to b-actin levels.
NMX, normoxia; HPX, hypoxia.
(C) Endogenous RSUME protein expression in brain tumors: one representative pituitary (nonfunctioning adenoma) and one glioma out of four tumors
are shown. Periphery, peripheral well-vascularized zone; Inner, inner partially necrotic zone.Cell 131, 309–323, October 19, 2007 ª2007 Elsevier Inc. 313
Figure 3. RSUME Enhances SUMO-Conjugation In Vivo and In Vitro
(A) COS-7 cells were transfected with 0.5 mg of RSUME, V5-Ubc9, and SENP-1 expression vectors. Forty-eight hours posttransfection, cell extracts
were subjected to WB. GAPDH was used as loading control.
(B) COS-7 cells were transfected with 0.5 mg of RSUME or ubiquitin expression vectors. Forty-eight hours posttransfection, cell extracts were sub-
jected to WB.
(C) SUMO-1 conjugation of recombinant IkB assayed in vitro in the presence or absence of 0.5 mg of recombinant RSUME protein or 0.5 mg of the
Y61A/P62A mutant RSUME protein. Reaction mixes were subjected to WB with anti-IkB. B: control protein extract purified from E.coli transformed
with the empty pQE30 vector.314 Cell 131, 309–323, October 19, 2007 ª2007 Elsevier Inc.
the protein, as previously suggested (Desterro et al.,
1998). Enhanced sumoylation of IkB by RSUME was
abolished when IkB was mutated at lysines 21 and 22,
both of which are SUMO-1 conjugation targets (Desterro
et al., 1998) (Figure 5A). Immunoprecipitation experiments
showed a direct interaction of RSUME with IkB (Fig-
ure 5B).
In order to determine whether there is a functional con-
sequence of IkB’s increased stability, we cotransfected
RSUME with a kB-LUC reporter vector and studied its
effects on TNF-a-induced transcriptional activity. RSUME
inhibited TNF-a-induced reporter activity to levels similar
to those obtained by overexpression of IkB or SUMO-1
(Figure 5C). Accordingly, small interference RNAs (siRNA)
specifically directed against RSUME stimulated NF-kB
transcriptional activity (Figure 5D). We then studied the
action of RSUME on two NF-kB targets. RSUME inhibited
interleukin-8 (IL-8) promoter activity (abolished when the
NF-kB binding site of the promoter was mutated)
(Figure 5E) and the expression of cyclooxigenase-2
(Cox-2) (Figure 5F).
Role of RSUME inHIF-1aActivation duringHypoxia
Hypoxia induces SUMO-1 expression (Shao et al., 2004),
and sumoylation of HIF-1a leads to its stabilization (Bae
et al., 2004). Given that RSUME is induced by hypoxia
(Figures 2B and 2C) and plays a role in sumoylation and
that sumoylation of some proteins with high molecular
weight is increased by hypoxia (Figure S2), we hypothe-
sized that RSUME might play a role in the cell’s response
to hypoxic stress.
HIF-1 is an heterodimer composedofHIF-1a andHIF-1b
subunits. HIF-1a is rapidly degraded via the ubiquitin-pro-
teasome pathway under normoxic conditions. Activation
ofHIF-1 by stabilization ofHIF-1aduring hypoxia regulates
adaptive responses to changes in oxygen tension and is
associated with various physiological and pathological
processes (Semenza, 2003; Pouyssegur et al., 2006). We
first transfected COS-7 cells with an RSUME expression
vector and determined HIF-1a protein levels. After 16 hr
hypoxic stress, RSUME expression increased HIF-1a pro-
tein levels, without affecting Ubc9 levels (Figure 6A). Re-
ciprocally, we observed an increase of RSUME transcripts
and promoter activity by hypoxia (bar 3 versus bar 1 and
bar 4 versus bar 2) and byHIF-1a in normoxia (bar 2 versusbar 1) (Figures 6B and 6C). However, the effect of HIF-1a
was less pronounced during hypoxia (bar 4 versus bar 3)
where HIF-1a levels are already high (Figures 6B and
6C). Deletion in theRSUMEpromoter of the consensus se-
quence (RCGTG) reported to be critical for HIF-1a binding
(Semenza et al., 1996; Bae et al., 2006) abolished the ob-
served effects (Figure 6C).
The role of endogenousRSUME levels onHIF-1a activa-
tion was studied using siRNA specifically directed against
RSUME. Downregulation of endogenous RSUME, con-
firmed by WB, resulted in the inhibition of endogenous
HIF-1a stabilization during hypoxia (Figure 6D). Accord-
ingly, a significant inhibition by RSUME siRNA was
observed on HIF-1a transcriptional activity when mea-
sured in an HRE-LUC reporter system (Figure 6E). Immu-
noprecipitation experiments detected HIF-1a in an extract
where RSUME was immunoprecipitated (Figure 6F), indi-
cating an interaction between RSUME and HIF-1a during
hypoxia that could account for the observed effects.More-
over, RSUME enhanced HIF-1a sumoylation both in vitro
(Figure 6G) and in cells, where RSUME siRNA diminished
HIF-1a sumoylation (Figure 6H). This supports a mecha-
nism in which RSUME participates in HIF-1a stabilization,
in line with the siRNA experiments shown in Figure 6D. As
a functional consequence of HIF-1a stabilization, during
hypoxia RSUME enhanced induction of promoter activity
(Figure 6I), and mRNA and protein expression (Figure 6J)
of a well-characterized HIF-1a target (Richard et al.,
1999), VEGF, further supporting the functional relevance
of the interaction between RSUME and HIF.
DISCUSSION
The RWD domain has been shown to have significant
structural similarity with the SUMO conjugase Ubc9
(Nameki et al., 2004) and has been proposed to have
a general function as protein-protein interaction motif.
Nevertheless, there is no previous experimental evidence
for its function in mammalian cells, and a specific bio-
chemical function for this domain has only been described
for the eIF2a kinase GCN2 in yeast (Kubota et al., 2000).
No function has been determined for Rwdd1 and Rwdd2
either. In this work, we performed a detailed experimental
analysis of RSUME, a small protein containing an RWD
domain. We found that RSUME enhances SUMO(D) 0.3 mg HA-SUMO-1, -2, and -3 expression vectors were cotransfected with 0.5 mg of RSUME, V5-Ubc9, and V5-Ubc9(C93S) expression vectors.
Forty-eight hours posttransfection, cell extracts were subjected to WB with anti-HA to detect sumoylated proteins. *: free SUMO, which was not de-
tected in the case of SUMO-1. RSUME expression was confirmed with anti-RSUME antibodies, and Ubc9 or Ubc9(C93S) expression was confirmed
with anti-V5 antibodies. GAPDH was used as loading control.
(E) Two-step sumoylation assay for IkB. Step 1: thioester formation reactions with GST-Ubc9 in the absence of substrate at 30C for 10 min. Step 2:
the GST-Ubc9 thioester obtained in step 1 was incubated with recombinant IkB at 30C for 5min. 0.5 mg of RSUMEwas added either in step 1 or step
2 as indicated. Reaction mixes were subjected to WB with anti-IkB.
(F) Ubc9-SUMO1 thioester formation reactions were performed in vitro in the presence or absence of 0.3 mg of recombinant RSUME protein for the
indicated times. Reactions were stopped with nonreducing gel loading buffer and subjected to WB with anti-Ubc9.
(G) Assays of poly-SUMO-2 and poly-SUMO-3 chain formation were performed with 5 mg of SUMO-3 or 8 mg GST-SUMO-2 in the presence or
absence of 0.3 mg of recombinant RSUME. Reaction mixes were subjected to WB.
(H) COS-7 cells were transfected with 0.5 mg of RSUME and HA-PIAS1 expression vectors as indicated. Forty-eight hours posttransfection, cell
extracts were subjected to WB. GAPDH was used as loading control.Cell 131, 309–323, October 19, 2007 ª2007 Elsevier Inc. 315
Figure 4. RSUME Directly Interacts with Ubc9
(A) 0.5 mg of recombinant RSUME was coprecipitated by GST-Ubc9 in vitro. Where indicated, 1.0 mg of SUMO-1 was included. Pull-down experi-
ments were performed, and samples were subjected to WB.
(B) 0.5 mg of recombinant RSUME and 0.5 mg of recombinant SUMO-1 were coimmunoprecipitated in RIPA with anti-RSUME or anti-SUMO-1 anti-
bodies. The immunoprecipitated fractions were subjected to WB with SUMO-1 antibodies.
(C) 0.5 mg of recombinant RSUME and 0.2–2.0 mg of recombinant SUMO-1 were coprecipitated by GST-Ubc9 in vitro pull-down experiments. Sam-
ples were subjected to WB.
(D) Two-step competition experiment. Step1: indicatedmixeswere incubated at 25C for 1 hr. Step 2: SUMO-1 or GST-Ubc9was added as indicated.
Samples were precipitated by GST-Ubc9 as in vitro pull-down experiments, and reaction mixes were subjected to WB.316 Cell 131, 309–323, October 19, 2007 ª2007 Elsevier Inc.
Figure 5. RSUME Stimulates IkB Sumoy-
lation and Inhibits NF-kB Transcriptional
Activity
(A) COS-7 cells were cotransfected with 0.5 mg
of IkB, IkB (K21,22R), and the indicated ex-
pression vectors to analyze in vivo IkB sumoy-
lation. Forty-eight hours posttransfection, cell
extracts were subjected to WB with anti-IkB
antibodies.
(B) 0.5 mg of recombinant RSUME and 0.5 mg of
recombinant IkB were coimmunoprecipitated
in RIPAwith anti-RSUME or anti-IkB antibodies
and subjected to WB.
(C and D) HepG2 cells were transfected with
0.5 mg of (NF-kB)3-LUC reporter vector and
0.5 mg of b-galactosidase control plasmid,
with 0.5 mg of RSUME, HA-SUMO1, or IkB ex-
pression vectors (C) or 20 mM of siRNAs di-
rected against RSUME or a scrambled siRNA
as a control (D). After 24 hr, cells were stimu-
lated with 10 ng/ml TNF-a for 6 hr, and lucifer-
ase (LUC) activity was measured in the cell
extracts. Each value was normalized to b-ga-
lactosidase activity, and results are expressed
as mean ± SEM of triplicates of one represen-
tative experiment of three experiments with
similar results. *p < 0.05 compared with cells
transfected with the empty vector stimulated
with TNF-a (ANOVA with Scheffe´’s test).
(E) HepG2 cells were transfected with 0.5 mg of
IL8-LUC or IL8(NFkBmut)-LUC reporter vector,
0.5 mg of RSUME, or HA-SUMO1 expression
vectors and 0.5 mg of b-galactosidase control
plasmid. After 24 hr, cells were stimulated
with 10 ng/ml TNF-a for 6 hr, and LUC activity
was measured in the cell extracts. Each value
was normalized to b-galactosidase activity,
and results are expressed as mean ± SEM of
triplicates of one representative experiment of
three experiments with similar results. *p <
0.05 compared with cells transfected with the
empty vector stimulated with TNF-a (ANOVA
with Scheffe´’s test).
(F) Glial 1321 cells were transfected with 0.5 mg
V5-RSUME or HA-SUMO-1 expression vec-
tors. Cells were subjected to 24 hr washout
without serum and stimulated with 2.5 ng/ml
IL-1 for 3 hr. Cell extracts were subjected to
WB. GAPDH was used as loading control.conjugation; this action depends on an intact RWD do-
main. Our study provides experimental evidence of a spe-
cific function for the RWD domain in a mammalian protein.
E1 and E2 have been shown to be sufficient for su-
moylation of various substrates in vitro. However, mostsumoylation reactions require E3 activity in vivo. RSUME
has functional similarities to SUMO ligases: it enhances
sumoylation in vitro and in vivo, colocalizes with Ubc9,
and interacts with GST-Ubc9 in pull-down experiments.
However, RSUME also increases the overall protein(E) E1 or Ubc9 were coprecipitated by GST-Ubc9 or GST-E1, respectively, in vitro in the presence or absence of 0.5 mg RSUME. Pull-down exper-
iments were performed, and samples were subjected to WB.
(F) Pull-down of RSUME transfected COS-7 extracts with GST-Ubc9. COS-7 cells transfected with V5-RSUME and HA-SUMO-1 expression vectors
were lysed in GST binding buffer and precipitated with GST-Ubc9. Precipitates were subjected to WB.
(G) COS-7 and HeLa cells transfected with 0.5 mg EGFP-RSUME and 0.5 mg RFP-Ubc9 expression vectors were fixed 48 hr posttransfection. Colo-
calization of EGFP-RSUME (green) and RFP-Ubc9 (red) was observed by confocal fluorescence microscopy. Merged images of both channels are
included, with yellow representing overlapping signal. One representative image of 30 observations from two independent experiments with similar
results is shown.Cell 131, 309–323, October 19, 2007 ª2007 Elsevier Inc. 317
Figure 6. Role of RSUME during Hypoxia
(A) COS-7 cells were transfected with 0.5 mg of V5-RSUME or the corresponding empty vector. Twenty-four hours posttransfection, cells were sub-
jected to hypoxic conditions (1%O2, 5%CO2, 94%N2) for 16 hr. Cell extracts were subjected toWB. NMX, normoxia; HPX, hypoxia. b-actin was used
as loading control.318 Cell 131, 309–323, October 19, 2007 ª2007 Elsevier Inc.
sumoylation and the SUMO targeting of several proteins,
thus pointing to a more general function as an enhancer
of SUMO conjugation. The stimulation by RSUME of the
dominant-negative effect of Ubc9(C93S) provides further
support for this notion. Moreover, the two-step in vitro
sumoylation experiment shows that RSUME has a stron-
ger effect during the thioester formation step but also en-
hances transfer to the substrate. Thus, RSUME acts on
two different phases of the sumoylation reaction: it en-
hances Ubc9-SUMO thioester formation and also the su-
moylation of specific substrates (i.e., IkB and HIF-1a, with
which RSUME interacts either directly or via Ubc9), with
a stronger action in the first phase (Figure 7). In contrast
to what is found in the ubiquitin pathway, in which E3s
are the primary determinants of target specificity, in the
SUMO pathway other alternatives may occur, for example
the E2 Ubc9 also directly recognizes several targets, such
as RanGAP1.
Even though only a small fraction of a given SUMO sub-
strate protein is sumoylated in vivo at any given time as
a result of dynamic sumoylation/desumoylation cycles,
deficient or excessive sumoylation can have dramatic
effects on the target protein function, making specific
and general regulators of SUMO conjugation essential.
The adenoviral protein Gam1 inhibits the SUMO pathway
by interfering with the activity of E1 (SAE1/SAE2). Gam1
inhibits the formation of the E1-SUMO thioester complex
and induces the disappearance of SAE1, SAE2, andUbc9 in vivo, resulting in an overall inhibition of protein
sumoylation (Boggio et al., 2004). Whereas Gam1 is a viral
protein inhibitor of protein sumoylation, RSUME is a cellu-
lar enhancer of the sumoylation machinery, which does
not affect E1 and Ubc9 levels and participates in specific
cellular contexts such as hypoxia.
Unlike the ubiquitination pathway that can use several
E2-conjugating enzymes, Ubc9 is the only known protein
that can function as a SUMO E2 (Desterro et al., 1997;
Gong et al., 1997). Accordingly, Ubc9-deficient mice die
at the early postimplantation stage (Nacerddine et al.,
2005). RSUME not only binds to Ubc9 and increases non-
covalent SUMO-1 binding but also enhances Ubc9 activ-
ity. RSUME also interacts with SUMO-1. SUMO-1 pre-
vents RSUME interaction with Ubc9 only in the higher
concentrations in certain dynamic situations in which the
heterodimer RSUME-Ubc9 has not yet assembled. Under
these conditions, SUMO-1 may also bind to additional
sites in RSUME that could partially overlap with the
RSUME-Ubc9 binding site, which, in analogy with the
Mms2-Ubc13 complex further discussed below, would
include the N-terminal helix (VanDemark et al., 2001; Ed-
dins et al., 2006).
The results showing the interaction of RSUME with the
SUMO conjugation proteins and the enhancement of the
formation of the E2-SUMO-1 thioester are in agreement
with RSUME acting as a sumoylation enhancer (Figure 7).
Noncovalent ubiquitin-like (Ubl) protein-E2 complexes are(B) COS-7 cells were transfected with HIF-1a expression vector or the corresponding empty vector. Twenty-four hours posttransfection, cells were
subjected to hypoxic conditions as in (A) for 16 hr, and RNA was extracted and amplified by RT-PCR to detect endogenous RSUME. Densitometric
values were normalized to b-actin levels.
(C) COS-7 cells were transfected with 0.5 mg of pRSUME-LUC or pRSUME-D-LUC reporter vector, 0.5 mg of HIF-1a expression vector, and 0.5 mg of
b-galactosidase control plasmid. Twenty-four hours posttransfection, cells were subjected to hypoxic conditions as in (A) for 16 hr, and LUC activity
was measured in the cell extracts. Each value was normalized to b-galactosidase activity, and results are expressed as mean ± SEM of triplicates of
one representative experiment of three experiments with similar results. *p < 0.05 compared with cells transfected with the empty vector. **p < 0.05
compared with the corresponding transfected cells under normoxic conditions (ANOVA with Scheffe´’s test).
(D) COS-7 cells were transfected with 20 mM siRNA directed against RSUME or Firefly Luciferase (LUCi) as a control. Twenty-four hours posttrans-
fection, cells were subjected to hypoxic conditions as in (A) for 16 hr. Cell extracts were subjected to WB. b-actin was used as loading control.
(E) COS-7 cells were transfected with 0.5 mg of HRE(V4R)-LUC reporter vector, 0.5 mg of HIF-1a or 0.5 mg of RSUME expression vector, 20 mM of
siRNAs directed against RSUME or a scrambled siRNA as a negative control, and pRL-TK control plasmid. Twenty-four hours posttransfection, cells
were subjected to hypoxic conditions as in (A) for 16 hr, and LUC activity was measured in cell extracts. Each value was normalized to Renilla lucif-
erase (pRL-TK) activity, and results are expressed as mean ± SEM of triplicates of one representative experiment of three experiments with similar
results. *p < 0.05 and **p < 0.01 compared with the corresponding cells transfected with the empty vector; #p < 0.05 compared with the correspond-
ing transfected cells not treated with siRNA directed against RSUME (ANOVAwith Scheffe´’s test). Inset: specificity of siRNA directed against RSUME
tested by WB.
(F) COS-7 cells were transfected with 1 mg of V5-RSUME and 1 mg of HA-HIF-1a expression vectors. Forty-eight hours posttransfection, cells were
lysed in RIPA buffer and immunoprecipitated with anti-HA or anti-V5 antibodies. The immunoprecipitated fractions and the whole lysates were sub-
jected to WB with anti-HIF-1a antibodies.
(G) SUMO-1 conjugation of recombinant GST-ODDdomain (amino acids 378–603) of HIF-1awas assayed in vitro in the presence or absence of 0.5 mg
of recombinant native RSUME protein. Reaction mixes were subjected to WB with anti-GST.
(H) COS-7 cells were transfected with 0.5 mg of RSUME expression vector, 20 mM of siRNAs directed against RSUME, or LUCi as a negative control.
Twenty-four hours posttransfection, cells were subjected to hypoxic conditions as in (A) for 16 hr. Cells were lysed in RIPA buffer and immunopre-
cipitated with anti- HIF-1a antibodies. The immunoprecipitated fractions were subjected to WBwith anti-HIF-1a. Anti-SUMO-1 WB is shown as con-
trol for the identity of the sumoylation band.
(I) COS-7 cells were transfected with 0.5 mg of VEGF-LUC reporter vector, 0.5 mg of RSUME, and 0.5 mg of b-galactosidase control plasmid. Twenty-
four hours posttransfection, cells were subjected to hypoxic conditions as in (A) for 16 hr, and luciferase activity was measured in the cell extracts.
Each value was normalized to b-galactosidase activity and results expressed as HPX/NMX % (mean ± SEM of triplicates of one representative
experiment of three experiments with similar results). *p < 0.05 compared with cells transfected with the empty vector (ANOVA with Scheffe´’s test).
(J) HeLa cells were transfected with 0.5 mg of RSUME expression vector or with the corresponding empty vector. Twenty-four hours posttransfection,
VEGF expression was assessed by RT-PCR and WB. b-actin was used as loading control. The three bands observed in the RT-PCR correspond to
three VEGF isoforms.Cell 131, 309–323, October 19, 2007 ª2007 Elsevier Inc. 319
Figure 7. Schematic Model for the Ac-
tions of RSUME on the Sumoylation Pro-
cess
(A) RSUME action on Ubc9-SUMO thioester
formation.
(B) RSUME action on the transference of
SUMO to the substrate and physiological con-
sequences.conserved platforms with important and differentiated
functions in the Ubl pathways (Capili and Lima, 2007;
Duda et al., 2007). The structure and functional implica-
tions of the noncovalent binding of SUMO to Ubc9 have
been described in detail very recently (Capili and Lima,
2007; Duda et al., 2007; Knipscheer et al., 2007). The anal-
ysis of several Ubc9 loss-of-function mutants has shown
that a reduction of noncovalent SUMO binding may in
some cases also perturb E1 interaction and can result in
different degrees of alteration of E2-thioester formation
(Capili and Lima, 2007; Knipscheer et al., 2007). Con-
versely, the presence of RSUME increases E1 and
SUMO binding to Ubc9. Given the importance of the E2-
E1 interaction in the progression of the transfer cascade
(Huang et al., 2007), this effect of RSUME can underlie
the observed increase in thioester formation. Future stud-
ies on the crystal structure of the RSUME-Ubc9 complex
and their interacting proteins will provide high-resolution
insights into these mechanisms.320 Cell 131, 309–323, October 19, 2007 ª2007 Elsevier Inc.Considering the structural similarity of the RWD domain
to UEVs (ubiquitin E2 variant proteins) and to E2s (Nameki
et al., 2004) and the fact that RSUME binds to Ubc9, these
two proteins (RSUME andUbc9) could form a heterodimer
analogous to the one found in the ubiquitination pathway
where the catalytically active Ubc13 binds the structurally
similar but catalytically inactive UEV Mms2 (VanDemark
et al., 2001; Eddins et al., 2006). In both cases, the catalyt-
ically inactive member of the heterodimer enhances the
activity of the E2 conjugase and consequently enhances
polymeric Ubl chain synthesis or, like the UEV-domain-
containing protein tumor susceptibility gene 101 (TSG101),
monoubiquitination. Beside UEVs, some ubiquitin-E2
noncovalent interactions have also been implicated in
polyubiquitin chain assembly (VanDemark et al., 2001;
Brzovic et al., 2006). In view of the aforementioned
structural homologies, the RSUME-Ubc9 heterodimer
enhances polysumoylation very likely via a platform
similar to that recently modeled for a Ubc9-Ubc9
homodimer (Knipscheer et al., 2007), based on the
Mms2-Ubc13 heterodimer that mediates ubiquitin
chain formation (VanDemark et al., 2001; Eddins
et al., 2006). The conservation described between the
ubiquitin and SUMO pathways is further expanded by
the structural and functional analogy of RSUME and
UEVs. RSUME could constitute an additional regulatory
point for the control of poly- or monosumoylation un-
der specific physiological conditions, such as hypoxia.
RSUME regulates two central players in mammalian an-
giogenesis and tumorigenesis. It inhibits NF-kB activity
through the stabilization of IkB, which leads to the inhibi-
tion of two of its targets, Cox-2 and IL-8, and activates
HIF-1a and consequently VEGF, one of its targets for vas-
cularization. NF-kB signaling plays a role in cancer devel-
opment and progression, controlling tumor angiogenesis,
invasiveness, and resistance to apoptosis (Karin, 2006).
Activation of HIF-1a is also a strong angiogenic stimulus
associated with a variety of tumorigenic processes and
has been suggested as a target for anticancer therapies
(Lee et al., 2004). RSUME is induced by hypoxia in tumors.
The finding of its expression in the necrotic zone of glio-
mas underscores the importance of RSUME during hyp-
oxia in tumorigenesis. Moreover, NF-kB and HIF-1a
have been proposed to interact in the regulation of angio-
genesis, since cells lacking HIF-1a show an increase in
NF-kB reporter activity in colon cancer cells (Mizukami
et al., 2005). Understanding the diverse pathways involved
in angiogenesis and tumorigenesis in which sumoylation
and its enhancer RSUME participate is essential to de-
velop better combined therapeutic strategies in the future.
EXPERIMENTAL PROCEDURES
Plasmids, Cloning, and Mutagenesis
Cloning and mutagenesis were performed with standard PCR-based
techniques. The nucleotide sequences of all constructs obtained by
PCR were confirmed by DNA sequencing. pAMP1-hRSUME, contain-
ing the hRSUME cDNA (clone ID: DKFZp566K023), was obtained from
the Resource Center for the German Human Genome Project. The fol-
lowing plasmids, were kindly provided by: (NF-kB)3-LUC by Dr. M.
Bell; IkB and IkB(K21R,K22R) expression vectors, V5-hUbc9, V5-
hUbc9(C93S), HA-SUMO-1, HA-SUMO-2, and HA-SUMO-3 by Dr.
R. Hay; HA-PIAS1 expression vector by Dr. C. Abate-Shen; Flag-
SENP1 by Dr. E. Yeh; HIF-1a expression vector by Dr. J. Pouyssegur;
pBI-GLV4R HRE-reporter plasmid by Dr. E. Van Meir; VEGF-LUC
reporter vector by Dr. E. Ng; IL8-LUC and IL8-LUC (NF-kBmut) by
Dr. N. Mukaida.
All plasmids used are described in detail in the Supplemental Exper-
imental Procedures.
Cell Culture
Unless otherwise stated, cell culture and reagents were obtained from
Invitrogen, Sigma Chemical Co., and MERCK. Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (pH 7.3) supplemented
with 10% FCS, 2.2 g/liter NaHCO3, 10 mMHEPES, 4 mM L-glutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin. Tumors were pro-
cessed for WB as previously described (Paez-Pereda et al., 2003).
For hypoxia, cells were incubated in 2% serum at 37C, 5% CO2,
and 1% O2 balanced with N2 using a sealed chamber. For CoCl2 stim-
ulation, cells were incubated in 2% serum with 150 mM CoCl2 for 3 hr.Transfections
Transfection assays with lipofectamine reagent (Invitrogen) were per-
formed as described (Kovalovsky et al., 2002). RSV-b-gal, coding for
the bacterial b-galactosidase gene under the control of the viral RSV
promoter, or pRL-Tk (Promega), coding for the Renilla luciferase
gene under the control of the viral thymidin kinase promoter, were
used as second reporter control plasmids.
Differential Display
A tumorigenic pituitary GH3 cell clone stably expressing gp130 (Perez
Castro et al., 2003) was used for differential display compared to GH3
cells transfected with the empty vector. Total RNA was isolated as
described (Arzt et al., 1992), and mRNA differential display was per-
formed with an RNAimage kit (Gene Hunter).
In Vitro SUMO Conjugation Assays
SUMO conjugation assays were performed following the manufac-
turer’s instructions using the Sumoylation Kit from LAE Biotech Inter-
national. Briefly, assays were carried out in a final volume of 20 ml in
reaction buffer containing 20 mM HEPES, 5 mM MgCl2, 2 mM ATP,
7.5 mg/ml E1, 50 mg/ml Ubc9, 50 mg/ml SUMO-1, 1.0 mg of the corre-
sponding substrate protein, and 0.5 mg of recombinant RSUME where
indicated. Reactionmixeswere incubated at 30C for 1 hr and stopped
by addition of 20 ml of a 23 Laemmly sample buffer.
Two-Step Sumoylation Assay
First step: reaction mixes containing 20 mM HEPES, 5 mM MgCl2,
2mMATP, 7.5 mg/ml E1, 50 mg/ml GST-E2 (Ubc9) bound to glutathione
Sepharose beads, and 50 mg/ml SUMO-1, but without substrate, were
incubated at 30C for 10 min. The reaction was stopped by washing
the beads twice with 20 mM HEPES, 5 mM EDTA, 50 mM NaCl, 1%
Tween-20. Second step: the beads with the GST-Ubc9 thioester
were incubated in 20 mM HEPES, 5 mM EDTA, 50 mM NaCl with
recombinant IkB at 30C for 5 min, and the reaction was stopped by
addition of 1 volume of a 23 Laemmly sample buffer. 0.5 mg of RSUME
was added either in the first or second step, as indicated.
Proteins were separated by SDS-PAGE and detected by WB with
the appropriate antibodies as described (Paez-Pereda et al., 2003).
Formation of Poly-SUMO-2 and Poly-SUMO-3 Chains
Assays were performed at 37C in buffer containing 20 mM HEPES,
10mMMgCl2, 50 mMNaCl, 7 mMATP, 1mMDTT, and an ATP-regen-
erating system. Reaction mixtures contained 10 mg/ml E1, 12.5 mg/ml
Ubc9, 5 mg of SUMO-3, or 8 mg GST-SUMO-2. When indicated, 0.3 mg
of recombinant RSUME was added. Proteins were separated by SDS-
PAGE and the SUMO-2- or SUMO-3-conjugated chains were de-
tected by WB with anti-SUMO-2/-3 antibodies. Bands of the top of
the gel indicated as poly-SUMO chains may include higher-order
SAE II conjugates that occur as a side effect of the reaction as
described (Knipscheer et al., 2007).
Thioester Formation Assay
Assays were carried out in a final volume of 15 ml in a buffer containing
20 mM HEPES, 10 mMMgCl2, 50 mM NaCl, 7 mM ATP, 7.5 mg/ml E1,
12.5 mg/ml E2 (Ubc9), and 50 mg/ml SUMO-1, without substrate and
with 0.3 mg of recombinant RSUME when indicated. Reaction mixes
were incubated at 37C for 15 or 30 min and stopped by incubating
at 37C for 30 min with 20 ml of nonreducing 23 sample buffer with
4 M urea or 10 mM DTT. Proteins were separated by SDS-PAGE,
and the thioester was detected by WB with anti-Ubc9 antibodies.
GST Pull-Down Assay
Three micrograms of GST or GST fusion proteins immobilized on
Sepharose beads were incubated with either 1 mg of the indicated re-
combinant proteins or COS-7 cell lysates transfected with an RSUME
expression vector for 1 hr at 4C in GST-binding buffer (20 mM Tris-
HCl [pH 7.4], 100 mM KCl, 2.5 mM CaCl2, 2.5 mM MgCl2, 1 mMCell 131, 309–323, October 19, 2007 ª2007 Elsevier Inc. 321
DTT, 0.5% NP-40, 1 mM PMSF). Samples were washed four times in
lysis buffer, boiled at 95C for 5 min in 23 Laemmly sample buffer,
and separated by SDS-PAGE.
Two-Step Competition Assay
First step: reaction mixes containing 0.5 mg of RSUME and 3 mg GST-
Ubc9 bound to glutathione Sepharose beads or 0.5 mg of RSUME and
0–2 mg of SUMO-1 in 10 ml of binding buffer (50 mM Tris-HCl [pH 7.5],
5 mM MgCl2, 5% glycerol, 50 mM NaCl, 1 mM DTT, 0.5 mM PMSF)
were incubated at 25C for 1 hr to pre-form protein complexes. Sec-
ond step: 0–2 mg of SUMO-1 or 3 mg GST-Ubc9 and 500 ml of binding
buffer were added to the reaction mixes and incubated at 25C for
30 min with agitation. Sepharose beads and bound proteins were
then pelleted, washed, and analyzed as in the GST pull-down assays.
Coimmunoprecipitation
COS-7 cells were cotransfected in 6-well plates with 1 mg V5-RSUME
and 1 mg HIF-1a expression vectors. Cells were subjected to hypoxia
for 16 hr, washed twice with ice-cold PBS, lysed on ice with modified
RIPA buffer, and immunoprecipitated with the indicated antibodies as
previously described (Paez-Pereda et al., 2003). For coimmunopreci-
pitation with recombinant proteins, 0.5 mg of each indicated recombi-
nant protein were precleared in RIPA buffer with 15 ml of protein A-aga-
rose beads for 1 hr and immunoprecipitated as indicated for cell
extracts. Beads were collected by centrifugation, washed four times
with 500 ml modified RIPA buffer, and boiled at 95C for 5 min in 23
Laemmly sample buffer before loading in SDS-PAGE gels. WB analy-
ses were performed with the indicated antibodies.
Statistics
Statistics were determined using ANOVA in combination with
Scheffe´’s test.
Further experimental information can be found in the Supplemental
Data.
Supplemental Data
The Supplemental Data for this article, including Supplemental Figures
and Experimental Procedures, can be found online at http://www.cell.
com/cgi/content/full/131/2/309/DC1/.
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